CLRB vs. RZLT, ABEO, IMUX, CRVS, ADAG, FGEN, CTXR, PMVP, RLMD, and ACET
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Rezolute (RZLT), Abeona Therapeutics (ABEO), Immunic (IMUX), Corvus Pharmaceuticals (CRVS), Adagene (ADAG), FibroGen (FGEN), Citius Pharmaceuticals (CTXR), PMV Pharmaceuticals (PMVP), Relmada Therapeutics (RLMD), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Cellectar Biosciences (NASDAQ:CLRB) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment.
Cellectar Biosciences received 185 more outperform votes than Rezolute when rated by MarketBeat users. However, 75.34% of users gave Rezolute an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
In the previous week, Cellectar Biosciences had 4 more articles in the media than Rezolute. MarketBeat recorded 18 mentions for Cellectar Biosciences and 14 mentions for Rezolute. Cellectar Biosciences' average media sentiment score of 0.63 beat Rezolute's score of 0.17 indicating that Cellectar Biosciences is being referred to more favorably in the media.
Cellectar Biosciences has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
Cellectar Biosciences presently has a consensus target price of $20.00, suggesting a potential upside of 511.62%. Rezolute has a consensus target price of $8.80, suggesting a potential upside of 221.17%. Given Cellectar Biosciences' higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Rezolute.
Rezolute's return on equity of -60.90% beat Cellectar Biosciences' return on equity.
16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 3.7% of Cellectar Biosciences shares are held by company insiders. Comparatively, 20.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Rezolute is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Rezolute beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
